What does the research say about de novo lipogenesis?
De novo lipogenesis (DNL) is the enzymatic conversion of non-lipid carbon sources into fatty acids. This page summarises what the research literature reports about the pathway, its rate-limiting enzyme FASN, and the tiss
What de novo lipogenesis is
De novo lipogenesis (DNL) is the metabolic pathway by which cells synthesise fatty acids from non-lipid carbon precursors, principally acetyl-CoA derived from carbohydrate and, to a lesser extent, amino acid catabolism. The pathway is cytosolic in animals and proceeds through the sequential action of acetyl-CoA carboxylase (ACC), which converts acetyl-CoA to malonyl-CoA, and the fatty acid synthase (FASN) multienzyme complex, which extends the acyl chain using malonyl-CoA units and NADPH as reducing equivalents. FASN is described in the literature as the rate-limiting enzyme of de novo lipogenesis [2]. The pathway is distinct from dietary lipid uptake and from fatty acid release via lipolysis; it represents net new fatty acid synthesis within a cell.
Research on DNL centres on the FASN enzyme complex and the broader lipogenic transcriptional programme, which in liver is regulated by sterol regulatory element-binding proteins (SREBPs) and carbohydrate-responsive element-binding protein (ChREBP). The pathway is studied in hepatocytes, adipocytes and cardiomyocytes, and its activity is commonly assessed by stable-isotope tracer methods, by expression of FASN and ACC, or by lipidomic profiling of the synthesised species.
Research Studies
FASN-mediated de novo lipogenesis and ceramide accumulation in arrhythmogenic cardiomyopathy
In arrhythmogenic cardiomyopathy (ACM), a heritable disease caused by desmosomal gene mutations and characterised by progressive myocardial loss and fibrofatty replacement, FASN was reported to be upregulated in cardiomyocytes of ACM patients and of a corresponding animal model [2]. The same work reported that FASN-mediated de novo lipogenesis promoted ceramide accumulation and myocardial damage in that disease context [2]. This finding is drawn from human tissue plus an animal model; it does not establish that DNL inhibition alters disease course in patients.
Hepatic de novo lipogenesis and non-alcoholic fatty liver disease
Non-alcoholic fatty liver disease (NAFLD) is defined as excessive lipid accumulation within hepatocytes in the absence of significant alcohol consumption or other causes of chronic liver disease, with a minimum histological criterion of greater than 5 percent steatosis [1]. NAFLD is reported to affect 25 to 30 percent of the global population and nearly one third of the population in North America [1]. Patients typically present with hepatic steatosis on imaging, elevated liver enzymes, and clinical features of insulin resistance, including pre-diabetes, type 2 diabetes mellitus, arterial hypertension, dyslipidaemia and visceral obesity [1]. Hepatic DNL is one of the pathways studied in this population because the liver is the principal site of FASN expression and because insulin resistance alters lipogenic transcriptional control.
Diet and hepatic transcriptomics in pre-diabetes
A registered study has examined how dietary intervention affects hepatic transcriptomic and lipidomic profiles in pre-diabetic participants, a population in which insulin resistance and hepatic steatosis frequently co-occur [1]. The study design links dietary exposure to changes in hepatic gene expression and lipid species, providing a human context in which lipogenic gene programmes can be assessed alongside clinical metabolic markers [1].
Comparing tissue contexts of de novo lipogenesis
The table below summarises the tissue contexts and evidence types reported in the sources above. It compares what each source describes rather than ranking them.
| Tissue / context | Reported finding | Evidence type | Source |
|---|---|---|---|
| Cardiomyocytes (ACM) | FASN upregulated; DNL promotes ceramide accumulation and myocardial damage | Human tissue plus animal model | [2] |
| Liver (NAFLD / pre-diabetes) | Hepatic steatosis above 5 percent; insulin resistance features; dietary effects on hepatic transcriptomics and lipidomics | Human study population | [1] |
FASN as the rate-limiting step
Across the sources, FASN is consistently positioned as the rate-limiting enzyme of de novo lipogenesis [2]. This means that measurements of FASN expression or activity are frequently used as a proxy for pathway flux, although the two are not identical: enzyme abundance does not by itself establish the rate of fatty acid synthesis in a given tissue.
Ceramides as a downstream species
In the ACM work, the reported consequence of elevated FASN-mediated DNL was ceramide accumulation, a lipid class associated with myocardial damage in that model [2]. This links a lipogenic enzyme to a specific sphingolipid outcome rather than to bulk triglyceride storage, and it is a finding specific to the ACM context studied.
Insulin resistance as a shared feature
The NAFLD population described in the clinical study is characterised by insulin resistance, including pre-diabetes, type 2 diabetes mellitus, arterial hypertension, dyslipidaemia and visceral obesity [1]. Because insulin signalling is a principal regulator of lipogenic gene expression, this population is the setting in which hepatic DNL is most often examined in human research.
Where the evidence is animal-only or in vitro
The ACM findings combine human tissue observations with an animal model, and the mechanistic claim that FASN-mediated DNL promotes ceramide accumulation and myocardial damage rests substantially on that model [2]. The hepatic transcriptomic and lipidomic work is conducted in a human pre-diabetic population but is a study of dietary response rather than of a DNL-targeted intervention [1]. No source in this evidence block reports a controlled human trial of a DNL-modulating agent with clinical endpoints.
If you are reading this for personal health reasons
The materials described on this page are sold for laboratory research use only. We do not provide dosing information, medical guidance, or recommendations for personal use of any compound. Anyone considering a compound for themselves should speak to a licensed clinician.